AEQUALIS PERFORM
Device
Stryker Corporation
Total Payments
$32.5M
Transactions
3,527
Doctors
1,334
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $7.8M | 1,182 | 630 |
| 2023 | $8.2M | 863 | 455 |
| 2022 | $8.9M | 893 | 433 |
| 2021 | $7.7M | 587 | 215 |
| 2020 | $712.68 | 2 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $31.3M | 619 | 96.1% |
| Consulting Fee | $765,212 | 387 | 2.4% |
| Unspecified | $290,361 | 58 | 0.9% |
| Food and Beverage | $143,387 | 2,240 | 0.4% |
| Travel and Lodging | $45,054 | 197 | 0.1% |
| Education | $11,457 | 25 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $2,500 | 1 | 0.0% |
Payments by Type
General
$32.2M
3,469 transactions
Research
$290,361
58 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TORNIER SHOULDER OUTCOMES CLINICAL STUDY | Stryker Corporation | $124,356 | 1 |
| TORNIER PERFORM STEMLESS REVERSE IDE STUDY (19B-W-PERFORM-R) | Stryker Corporation | $60,987 | 2 |
| PYROCARBON CLINICAL FOLLOW-UP STUDY (20A-W-PYC-RM) | Stryker Corporation | $48,561 | 0 |
| PERFORM HUMERAL SYSTEM STUDY (PHS) | Stryker Corporation | $34,557 | 0 |
| ONLAY VERSUS INLAY HUMERAL COMPONENT IN REVERSE TOTAL SHOULDER ARTHROPLASTY: A PROSPECTIVE, RANDOMIZED TRIAL | Stryker Corporation | $17,500 | 0 |
| INTERNAL ROTATION LIMITATION FOLLOWING REVERSE SHOULDER ARTHROPLASTY: PROPOSAL TO INVESTIGATE THE MECHANISM AND THE POTENTIAL ROLE OF CONJOINT TENDON LENGTHENING AS A SOLUTION | Stryker Corporation | $2,850 | 0 |
| PYROCARBON IDE | Stryker Corporation | $1,549 | 0 |
Top Doctors Receiving Payments for AEQUALIS PERFORM — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , D.O | Orthopaedic Surgery | Hudson, FL | $5,200 | 3 |
| , M.D | Emergency Medicine | Baton Rouge, LA | $5,200 | 1 |
| , MD | Sports Medicine | Arlington, VA | $4,797 | 4 |
| , MD | Orthopaedic Surgery | Saint Louis, MO | $4,704 | 17 |
| , MD | Orthopaedic Surgery | Warrenville, IL | $4,600 | 1 |
| , MD, PHD | Orthopaedic Surgery | Boise, ID | $4,448 | 38 |
| , M.D | Sports Medicine | Council Bluffs, IA | $4,316 | 7 |
| , MD | Orthopaedic Surgery | Sioux Falls, SD | $4,295 | 12 |
| , MD | Sports Medicine | Bradenton, FL | $4,208 | 7 |
| , MD | Sports Medicine | Oakland Park, FL | $4,000 | 1 |
| , M.D | Orthopaedic Surgery | Palm Beach Gardens, FL | $3,874 | 3 |
| , M.D | Specialist | Milwaukee, WI | $3,600 | 2 |
| , M.D | Orthopaedic Surgery | Orlando, FL | $3,496 | 12 |
| , M.D. M.M.SC | Orthopaedic Surgery | Philadelphia, PA | $3,494 | 7 |
| , MD | Sports Medicine | Oneonta, NY | $3,461 | 13 |
| , MD | Orthopaedic Surgery | Leonardtown, MD | $3,454 | 3 |
| , MD | Orthopaedic Surgery | Florence, KY | $3,400 | 2 |
| , MD | Orthopaedic Surgery | Hershey, PA | $3,375 | 4 |
| , M.D | Orthopaedic Surgery | New York, NY | $3,000 | 1 |
| Albert Lin | Sports Medicine | Pittsburgh, PA | $2,621 | 2 |
| , MD | Pediatric Orthopaedic Surgery | Iowa City, IA | $2,566 | 12 |
| , MD | Orthopaedic Surgery | Little Rock, AR | $2,546 | 1 |
| , MD | Hand Surgery | Atlanta, GA | $2,450 | 2 |
| , M.D | Orthopaedic Surgery | Houston, TX | $2,363 | 28 |
| , MD | Orthopaedic Surgery | Kansas City, MO | $2,338 | 3 |
Ad
Manufacturing Companies
- Stryker Corporation $32.5M
Product Information
- Type Device
- Total Payments $32.5M
- Total Doctors 1,334
- Transactions 3,527
About AEQUALIS PERFORM
AEQUALIS PERFORM is a device associated with $32.5M in payments to 1,334 healthcare providers, recorded across 3,527 transactions in the CMS Open Payments database. The primary manufacturer is Stryker Corporation.
Payment data is available from 2020 to 2024. In 2024, $7.8M was paid across 1,182 transactions to 630 doctors.
The most common payment nature for AEQUALIS PERFORM is "Royalty or License" ($31.3M, 96.1% of total).
AEQUALIS PERFORM is associated with 7 research studies, including "TORNIER SHOULDER OUTCOMES CLINICAL STUDY" ($124,356).